Rule 2.7, 3.10.3, 3.10.4, 3.10.5
application for quotation of additional securities and agreementInformation or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12
Name of entity |
CYNATA THERAPEUTICS LIMITED |
ABN |
98 104 037 372 |
We (the entity) give ASX the following information.
Part 1 - All issuesYou must complete the relevant sections (attach sheets if there is not enough space).
1 | +Class of +securities issued or to be issued | Fully Paid Ordinary Shares subject to voluntary escrow for 12 months |
2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued | 8,088,403 |
3 | Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | Fully Paid Ordinary Shares subject to voluntary escrow for 12 months |
4 | Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state:
| Yes. |
5 | Issue price or consideration | $0.49113 |
6 | Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) | Issued to FUJIFILM Corporation of Japan under a license option agreement for the development and commercialisation of certain Cynata technology at a 35% premium to the 6 month VWAP as at 2 September 2016, the date of execution of the non-binding term sheet. |
6a | Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i | Yes |
6b | The date the security holder resolution under rule 7.1A was passed | 16 November 2016 |
6c | Number of +securities issued without security holder approval under rule 7.1 | 8,088,403 |
6d | Number of +securities issued with security holder approval under rule 7.1A | N/A |
6e | Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) | N/A | |
6f | Number of securities issued under an exception in rule 7.2 | N/A | |
6g | If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation. | N/A | |
6h | If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements | N/A | |
6i | Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements | 7.1 2,822,308 7.1A 7,273,807 | |
7 | Dates of entering +securities into uncertificated holdings or despatch of certificates | 25 January 2017 | |
Number | +Class | ||
8 | Number and +class of all +securities quoted on ASX (including the securities in section 2 if applicable) | 80,826,478 | Fully Paid Ordinary Shares (CYP) |
Number | +Class |
5,000,000 3,666,669 750,000 600,000 800,000 | Unlisted Options exercise price $0.40, expiring 27 September 2018 (CYPAI). Unlisted Options exercise price $1.00, expiring 17 July 2020 (CYPAM). Unlisted Incentive Options exercise price$0.49 expiring 16 December 2018 (500,000 subject to vesting conditions). Unlisted Options exercise price $0.53, expiring 22 February 2019. Unlisted Options exercise price $1.022, expiring 17 November 2019 (subject to 12 month vesting condition) |
9 Number and +class of all
+securities not quoted on ASX (including the securities in section 2 if applicable)
10 | Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) | N/A |
11 | Is security holder approval required? | N/A |
12 | Is the issue renounceable or non- renounceable? | N/A |
13 | Ratio in which the +securities will be offered | N/A |
14 | +Class of +securities to which the offer relates | N/A |
15 | +Record date to determine entitlements | N/A |
16 | Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? | N/A |
Cynata Therapeutics Ltd. published this content on 25 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 25 January 2017 08:26:08 UTC.
Original documenthttp://cynata.com/wp-content/uploads/2017/01/17.01.25.Appendix-3B-Receipt-of-Funds-Issue-of-Shares-to-Fujifilm.pdf
Public permalinkhttp://www.publicnow.com/view/E53D0E57694AD020BFAD5842C72668A2B5C98116